MedAdvisor Solutions Seeks $7 million Capital Raise to Drive Growth

Key Highlights:

• MedAdvisor Solutions (ASX: MDR) is raising A$7 million through a share placement and purchase plan.
• The capital will support strategic growth and cost-reduction initiatives.
• At the time of writing, the offer price stands at A$0.10 per share, reflecting a 9.1% discount to the last closing price.

Capital Raise to Strengthen Financial Position

MedAdvisor Solutions (ASX: MDR), a leading provider of pharmacy-driven patient engagement solutions, has announced a capital raise of up to A$7 million to accelerate its strategic initiatives and cost optimization programs. The funding will be sourced through an institutional placement of A$5 million and a share purchase plan (SPP) for eligible investors, raising an additional A$2 million.

Strategic Use of Funds

The proceeds will be allocated towards working capital and supporting the company’s Transformation 360⁰ initiative, which is projected to save A$5 million in FY26. Additionally, MedAdvisor Solutions has identified further cost-cutting measures, expected to reduce operating expenses by A$3.4 million in the same period.

Market Response and Valuation

At the time of writing, the offer price of A$0.10 per share represents a 9.1% discount to the last closing price and a 1.2% discount to the 5-day VWAP (Volume-Weighted Average Price) as of March 28, 2025.

Despite recent challenges, the company remains optimistic, citing strong demand for its digital patient engagement programs in the U.S. and ANZ markets. With a forecasted revenue of A$93M–A$99M for FY25, MedAdvisor Solutions is positioning itself for long-term sustainable growth.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. aThe primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com